[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352198-105":59,"doc-detail-352198-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","engineering-editopes-through-programmable-rna-editing-toward-tumor-neoantigen-generation","Engineering editopes through programmable RNA editing toward tumor neoantigen generation","","Neoepitope-targeted cancer immunotherapies show strong potential because they focus on tumor-specific mutations and stimulate effective anti-tumor T-cell activity. Clinical use is constrained by difficulties in neoepitope discovery and uncertainty about how tumor cells present these targets. A programmable RNA-editing approach offers an alternative: generating immunogenic neoepitopes inside cancer cells by precise adenosine-to-inosine editing. This work introduces SPEAR gRNAs, demonstrates editotope formation with restored T-cell recognition, enables in vivo tumor control, and provides a computational pipeline to identify tumor-selective candidates across cancer types.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/engineering-editopes-through-programmable-rna-editing-toward-tumor-neoantigen-generation/352198/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/engineering-editopes-through-programmable-rna-editing-toward-tumor-neoantigen-generation/352198.png","ImageObject",300,407,{"name":92,"@type":93},"MrHarris58","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem limits neoepitope-based cancer immunotherapies in the clinic?","Question",{"text":112,"@type":113},"Clinical implementation is limited by the complexity of neoepitope discovery and uncertainty about whether and how tumor cells present the neoepitopes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the SPEAR strategy create immunogenic targets in this work?",{"text":117,"@type":113},"SPEAR gRNAs recruit endogenous ADAR1 to perform precise A-to-I (adenosine-to-inosine) RNA editing at chosen transcript sites, generating immunogenic neoepitopes termed editopes at the RNA level.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports the approach in vivo and for antigen-specific recognition?",{"text":121,"@type":113},"In a melanoma antigen MART-1 proof-of-concept model, SPEAR-mediated RNA editing restores antigen-specific T-cell recognition and enables tumor control in vivo.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352198,1790204449,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":26,"preview_page_count":19,"preview_urls":145},687212988360,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Method  \nEngineering editopes through programmable RNA editing toward tumor neoantigen generation  \nRiccardo Pecori 1,18, Beatrice Casati 1,18, Rona Merdler-Rabinowicz 2,3,18, Netanel Landesman 3, Khwab Sanghvi4,5, Stefan Zens 6,7, Ece Bilgin 1, Mantiana Topouzi 1, Kai Kipfstuhl6,7,  \nVeronica Pinamonti 8,9, Annette Arnold1, Mohammad Abukhalaf 10,11, David Gomez-Zepeda 10,12, Stefan Tenzer  10,11,13, John M Lindner  9, Michael Platten4,5,10,14,15,16, Rienk Offringa6,7,  \nRafael Carretero 7,17, Eytan Ruppin 2 , Erez Y Levanon 3  & Fotini Nina Papavasiliou 1   \nAbstract  \nNeoepitope-based therapies hold great promise for cancer immunotherapy because they target tumor-speciﬁc mutations and elicit potent anti-tumor T-cell responses. However, their clinical implementation remains limited by the complexity of neoepitope discovery and uncertainty regarding presentation by tumor cells. A potential alternative is the generation of immunogenic neoepitopes directly within cancer cells through programmable RNA editing. Here, we develop Short Precise-Encodable ADAR Recruiting (SPEAR) gRNAs that harness endogenous ADAR1 to direct precise adenosine-to-inosine (A-to-I) editing at selected transcript sites. Using these gRNAs, we demonstrate the generation of immunogenic neoepitopes through RNA editing at the transcript level, termed editopes. In a proof-of-concept model based on the melanoma antigen MART-1, SPEAR-mediated RNA editing restored antigen-speciﬁc T cell recognition and enabled tumor control in vivo. Finally, we developed a computational pipeline to identify candidate tumor-selective neoepitopes across multiple cancer types amenable to guided RNA editing. Our ﬁndings establish programmable RNA editing as a strategy for engineering immunogenic editopes and provide a framework for neoepitope-directed cancer immunotherapy.  \nSubject Categories Cancer; Immunology; RNA Biology  \n[https://doi.org/10.1038/s44318-026-00870-5](https://doi.org/10.1038/s44318-026-00870-5)  \nReceived 24 November 2025; Revised 21 June 2026; Accepted 22 June 2026  \nPublished online: 14 August 2026  \nIntroduction  \nIn recent years, immunotherapy has emerged as a revolutionary approach in cancer therapy, demonstrating remarkable clinical response in numerous cases with acceptable patient risk (Esfahaniet al, 2020) . This success depends on the ability to trigger a robust immune response against the tumor and requires both the presence of cancer-speciﬁc antigens on tumor cells and T lymphocytes bearing antigen-speciﬁc T cell receptors (TCR) that recognize and kill them. Responsiveness to immunotherapy is positively correlated with tumor mutational burden (TMB) (Chan et al, 2019; Yarchoan et al, 2017; Samstein et al, 2019) . Since only a subset of somatic mutations give rise to neoepitopes that are processed and presented as non-self by the major histocompatibility complex (MHC), tumors with a high TMB are more likely to produce immunogenic neoantigens and to respond favorably to immunotherapy (Schumacher and Schreiber, 2015) .  \nNeoantigens arise from non-synonymous DNA mutations, but also from aberrant post-transcriptional and post-translational modiﬁcations, including aberrant mRNA translation, alternative splicing, and RNA editing (Nagel et al, 2022; Zhang et al, 2018; Smart et al, 2018) . However, many cancers harbor an insufﬁcient repertoire of neoantigens capable of eliciting a strong immune reaction (Bonaventura et al, 2019) and are therefore poorly responsive to immunotherapy. To address this challenge, strategies aimed at artiﬁcially enhancing neoantigen production have emerged, such as modulation of alternative splicing (Lu et al, 2021) . Yet, these approaches are not tumor-speciﬁc and can often also affect healthy tissues, potentially leading to adverse side effects, such as autoimmunity. Effective methods to generate speciﬁcneoantigens exclusively within tumor cells are still lacking.  \n1Division of Immune Diversity, German Cancer Research Center (DKFZ),","cbCaimWX7osSCH4H","https://ap.wps.com/l/cbCaimWX7osSCH4H","pdf",4285508,24,"English","# Abstract\n## Introduction\n## Method","[{\"question\":\"What problem limits neoepitope-based cancer immunotherapies in the clinic?\",\"answer\":\"Clinical implementation is limited by the complexity of neoepitope discovery and uncertainty about whether and how tumor cells present the neoepitopes.\"},{\"question\":\"How does the SPEAR strategy create immunogenic targets in this work?\",\"answer\":\"SPEAR gRNAs recruit endogenous ADAR1 to perform precise A-to-I (adenosine-to-inosine) RNA editing at chosen transcript sites, generating immunogenic neoepitopes termed editopes at the RNA level.\"},{\"question\":\"What evidence supports the approach in vivo and for antigen-specific recognition?\",\"answer\":\"In a melanoma antigen MART-1 proof-of-concept model, SPEAR-mediated RNA editing restores antigen-specific T-cell recognition and enables tumor control in vivo.\"}]","Engineering editopes through programmable RNA editing toward tumor neoantigen generation | PDF",1790098266,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/800ae66375f5d9f3a5d80cf5e45f829a.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e26a0f7332eb93edcca91df08e6354e4.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b38c9fd0c64ee27b5bacacf0d3b9f31.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b63aa384d1753e273aeedcb64b730159.webp",980,1301]